• 1
    Devroede GJ,Taylor WF,Sauer WG,Jackman RJ,Stickler GB. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971; 285: 1721.
  • 2
    Goldgraber MB,Kirsner JB. Carcinoma of the colon in ulcerative colitis. Cancer 1964; 17: 65765.
  • 3
    Smalley W,Ray WA,Daugherty J,Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 1616.
  • 4
    Collet JP,Sharpe C,Belzile E,Boivin JF,Hanley J,Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81: 628.
  • 5
    Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 557589.
  • 6
    Camp NJ,Slattery ML. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control 2002; 13: 81323.
  • 7
    Slattery ML,Samowitz W,Hoffman M,Ma KN,Levin TR,Neuhausen S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 2004; 13: 53845.
  • 8
    Slattery ML,Curtin K,Wolff R,Ma KN,Sweeney C,Murtaugh M,Potter JD,Levin TR,Samowitz W. PPARγ and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 2006; 17: 23949.
  • 9
    Slattery ML,Curtin K,Ma K,Edwards S,Schaffer D,Anderson K,Samowitz W. Diet activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomarkers Prev 2002; 11: 5418.
  • 10
    Slattery ML,Anderson K,Curtin K,Ma K,Schaffer D,Edwards S,Samowitz W. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001; 483: 7381.
  • 11
    Slattery ML,Curtin K,Sweeney C,Levin TR,Potter J,Wolff RK,Albertsen H,Samowitz WS. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007; 120: 65663.
  • 12
    Slattery ML,Curtin K,Anderson K,Ma KN,Ballard L,Edwards S,Schaffer D,Potter J,Leppert M,Samowitz WS. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92: 18316.
  • 13
    Federico A,Morgillo F,Tuccillo C,Ciardiello F,Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121: 23816.
  • 14
    Slattery ML, Wolff RK, Curtin K, Jitzpatrick F, Harrick J, Potter JD, Caan BJ, Simowitz WS. Colon tumor mutations and epigenetic changes associated with genetic polymorphisms: Insight into disease pathways. Mutat Res 2009: 660: 1221.
  • 15
    Ferrari SL,Ahn-Luong L,Garnero P,Humphries SE,Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003; 88: 2559.
  • 16
    Bennermo M,Held C,Stemme S,Ericsson CG,Silveira A,Green F,Tornvall P. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem 2004; 50: 213640.
  • 17
    Hussain SP,Amstad P,Raja K,Ambs S,Nagashima M,Bennett WP,Shields PG,Ham AJ,Swenberg JA,Marrogi AJ,Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 33337.
  • 18
    Itzkowitz SH,Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7G17.
  • 19
    Slattery ML,Potter J,Caan B,Edwards S,Coates A,Ma KN,Berry TD. Energy balance and colon cancer—beyond physical activity. Cancer Res 1997; 57: 7580.
  • 20
    Slattery ML,Edwards S,Curtin K,Ma K,Edwards R,Holubkov R,Schaffer D. Physical activity and colorectal cancer. Am J Epidemiol 2003; 158: 21424.
  • 21
    Samowitz WS,Albertsen H,Herrick J,Levin TR,Sweeney C,Murtaugh MA,Wolff RK,Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 83745.
  • 22
    Samowitz WS,Albertsen H,Sweeney C,Herrick J,Caan BJ,Anderson KE,Wolff RK,Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 17318.
  • 23
    Issa JP,Shen L,Toyota M. CIMP, at last. Gastroenterology 2005; 129: 11214.
  • 24
    Slattery ML,Wolff RK,Herrick JS,Caan BJ,Potter JD. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 2007; 18: 1095105.
  • 25
    Landi S,Moreno V,Gioia-Patricola L,Guino E,Navarro M,de Oca J,Capella G,Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor α, NFKB1, and peroxisome proliferator-activated receptor γ with colorectal cancer. Cancer Res 2003; 63: 35606.
  • 26
    Edwards S,Slattery ML,Mori M,Berry TD,Caan BJ,Palmer P,Potter JD. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994; 140: 10208.
  • 27
    Slattery ML,Caan BJ,Duncan D,Berry TD,Coates A,Kerber R. A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc 1994; 94: 7616.
  • 28
    Slattery ML,David R,Jacobs J. Assessment of ability to recall physical activity of several years ago. Ann Epidemiol 1995; 5: 2926.
  • 29
    Slattery ML,Edwards SL,Ma K-N,Friedman GD,Potter JD. Physical activity and colon cancer: a public health perspective. Ann Epidemiol 1997; 7: 13745.
  • 30
    McDonald A,Van Horn L,Slattery M,Hilner J,Bragg C,Caan B,Jacobs D,Jr,Liu K,Hubert H,Gernhofer N,Betz E,Havlik D. The CARDIA dietary history: development, implementation, and evaluation. J Am Diet Assoc 1991; 91: 110412.
  • 31
    Liu K,Slattery M,Jacobs D,Jr,Cutter G,McDonald A,Van Horn L,Hilner JE,Caan B,Bragg C,Dyer A, Havlik R. A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis 1994; 4: 1527.
  • 32
    Slattery ML,Edwards SL,Anderson K,Caan B. Vitamin E and colon cancer: is there an association? Nutr Cancer 1998; 30: 2016.
  • 33
    Slattery ML,Benson J,Curtin K,Ma KN,Schaeffer D,Potter JD. Carotenoids and colon cancer. Am J Clin Nutr 2000; 71: 57582.
  • 34
    Friedman GD,Coates AO,Potter JD,Slattery ML. Drugs and colon cancer. Pharmacoepidemiol Drug Saf 1998; 7: 99106.
  • 35
    Slattery ML,Curtin K,Anderson K,Ma KN,Edwards S,Leppert M,Potter J,Schaffer D,Samowitz WS. Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res 2000; 60: 693541.
  • 36
    Krinsky NI,Deneke SM. Interaction of oxygen and oxy-radicals with carotenoids. J Natl Cancer Inst 1982; 69: 20510.
  • 37
    Sies H,Stahl W. Lycopene: antioxidant and biological effects and its bioavailability in the human. Proc Soc Exp Biol Med 1998; 218: 1214.
  • 38
    Micozzi MS,Beecher GR,Taylor PR,Khachik F. Carotenoid analyses of selected raw and cooked foods associated with a lower risk for cancer. J Nat Cancer Inst 1990; 82: 2825.
  • 39
    Britton G. Structure and properties of carotenoids in relation to function. FASEB J 1995; 9: 15518.
  • 40
    Enger SM,Longnecker MP,Chen MJ,Harper JM,Lee ER,Frankl HD,Haile RW. Dietary intake of specific carotenoids and vitamins A, C, and E, and prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1996; 5: 14753.
  • 41
    Slattery ML,Curtin K,Ma K,Schaffer D,Potter J,Samowitz W. GSTM-1 and NAT2 and genetic alterations in colon tumors. Cancer Causes Control 2002; 13: 52734.
  • 42
    Hussain SP,Harris CC. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 1999; 428: 2332.
  • 43
    Vasington FD,Reichard SM,Nason A. Biochemistry of vitamin E. Vitam Horm 1960; 18: 4387.
  • 44
    Cooney RV,Franke AA,Harwood PJ,Hatch-Pigott V,Custer LJ,Mordan LJ. γ-tocopherol detoxification of nitrogen dioxide: superiority to α-tocopherol. Proc Natl Acad Sci USA 1993; 90: 17715.
  • 45
    Murtaugh MA,Ma KN,Benson J,Curtin K,Caan B,Slattery ML. Antioxidants, carotenoids, and risk of rectal cancer. Am J Epidemiol 2004; 159: 3241.
  • 46
    Steffan RJ,Matelan E,Ashwell MA,Moore WJ,Solvibile WR,Trybulski E,Chadwick CC,Chippari S,Kenney T,Winneker RC,Eckert A,Borges-Marcucci L, et al. Control of chronic inflammation with pathway selective estrogen receptor ligands. Curr Top Med Chem 2006; 6: 10311.
  • 47
    De Bosscher K,Vanden Berghe W,Haegeman G. Cross-talk between nuclear receptors and nuclear factor κB. Oncogene 2006; 25: 686886.
  • 48
    Kurebayashi S,Miyashita Y,Hirose T,Kasayama S,Akira S,Kishimoto T. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. J Steroid Biochem Mol Biol 1997; 60: 1117.
  • 49
    Slattery ML,Curtin K,Baumgartner R,Sweeney C,Byers T,Giuliano AR,Baumgartner KB,Wolff RR. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007; 16: 74755.
  • 50
    Hussain SP,Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 237380.
  • 51
    Hofseth LJ,Saito S,Hussain SP,Espey MG,Miranda KM,Araki Y,Jhappan C,Higashimoto Y,He P,Linke SP,Quezado MM,Zurer I, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003; 100: 1438.
  • 52
    Wink DA,Hanbauer I,Grisham MB,Laval F,Nims RW,Laval J,Cook J,Pacelli R,Liebmann J,Krishna M,Ford PC,Mitchell JB. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curr Top Cell Regul 1996; 34: 15987.
  • 53
    Cooke MS,Evans MD,Dizdaroglu M,Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17: 1195214.
  • 54
    Abu-Amero KK,Alzahrani AS,Zou M,Shi Y. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome. Oncogene 2006; 25: 67784.